With Ascenion‘s help, the MDC established a unique translational centre in 2016 - the ‚Max-Delbrück Center Cell Engineering Lab‘ (MD-CEL). Its goal is to advance a completely new concept of cell-based gene therapy for cancer. Precisely because the approach is so new, there are many challenges to be overcome on the way to clinical application. This requires partners with experience in all relevant sectors: from scientific research to production and clinical development. For this reason, scientists at MD-CEL work at very early project stages with three industrial companies. The development work is jointly financed: partly by the industry partners, and partly by the Helmholtz Association (as Helmholtz Innovation Lab).
